Paxlovid can reduce the risk of hospitalization or death by 89% when taken shortly after testing positive for COVID-19. This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about Paxlovid: what it is,…
On March 3, 2022, we presented the first "Talk About It with TAG" webinar. This series addresses the needs of community members by having open discussions with researchers and community experts on issues related to COVID-19 and HIV biomedical research.
TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.
On August 31, 2021, Treatment Action Group (TAG) and Black AIDS Institute (BAI) held a community discussion to get the latest updates on the impact of the Delta variant.
TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.
This report aims to raise the profile of discussions that have been taking place regarding community understanding and involvement in COVID-19 vaccine research. It presents the results of an online survey developed by TAG, along with the Black AIDS Institute and the COVID-19 Prevention Trials Network in the fall of 2020 seeking community perspectives on COVID-19 vaccine development.
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.
On April 29, Treatment Action Group hosted this discussion with Dr. Ulysses Burley III Founder of UBtheCURE, and Faith Ambassador for the COVID-19 Prevention Trials Network, and Elder Carmarion D. Anderson-Harvey, Alabama State Director for the Human Rights Campaign, and Dr. B. Angeloe Burch Sr. Executive Director African American Community Collaborative.
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.